Allogene Therapeutics, Inc. (ALLO) — Analyst outlook / Analyst consensus target is. Based on 29 analyst ratings, the consensus is bullish — 19 Buy, 8 Hold, 2 Sell.
The consensus price target is $29.00 (low: $7.00, high: $55.00), representing an upside of 1171.9% from the current price $2.28.
Analysts estimate Earnings Per Share (EPS) of $-1.33 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.32 vs est $-1.33 (beat +0.9%). 2025: actual $-0.87 vs est $-0.93 (beat +6.1%). Analyst accuracy: 96%.
ALLO Stock — 12-Month Price Forecast
$29.00
▲ +1,171.93% Upside
Average Price Target
Based on 29 Wall Street analysts offering 12-month price targets for Allogene Therapeutics, Inc., the average price target is $29.00, with a high forecast of $55.00, and a low forecast of $7.00.
The average price target represents a +1,171.93% change from the last price of $2.28.
Highest Price Target
$55.00
Average Price Target
$29.00
Lowest Price Target
$7.00
ALLO Analyst Ratings
Buy
Based on 29 analysts giving stock ratings to Allogene Therapeutics, Inc. in the past 3 months
EPS Estimates — ALLO
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.32
vs Est –$1.33
▲ 1.0% off
2025
Actual –$0.87
vs Est –$0.93
▲ 6.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ALLO
91%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▼ 8.5% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
